Добірка наукової літератури з теми "Talidomide"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Talidomide".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Talidomide"
Scalzulli, Potito Rosario, Maria Rosa Valvano, Carlo C. Bodenizza, Angelo Michele Carella, Matteo M. Dell’Olio, Antonietta A. P. Falcone, Michele Mario Greco, et al. "Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience." Blood 110, no. 11 (November 16, 2007): 5117. http://dx.doi.org/10.1182/blood.v110.11.5117.5117.
Повний текст джерелаIberico Barrera Jefe del Servicio de Neumología, C. A., A. R. Llontop Calderón Residente, F. Romero Farromeque, and C. Yncarroca Huapaya. "EXPERIENCE OF PROLONGED TIME OF USE OF TALIDOMIDE FOR THE TREATMENT OF COUGH OF DIFFICULT CONTROL IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS." Chest 155, no. 4 (April 2019): 130A. http://dx.doi.org/10.1016/j.chest.2019.02.122.
Повний текст джерелаMenzinger, S., and E. Laffitte. "Talidomida." EMC - Dermatología 49, no. 4 (December 2015): 1–9. http://dx.doi.org/10.1016/s1761-2896(15)74836-3.
Повний текст джерелаPenna, Gerson Oliveira, Celina M. T. Martelli, Mariane M. A. Stefani, Vanize O. Macedo, Maria de Fátima Maroja, and Aiçar Chaul. "Talidomida no tratamento do eritema nodoso hansênico: revisão sistemática dos ensaios clínicos e perspectivas de novas investigações." Anais Brasileiros de Dermatologia 80, no. 5 (October 2005): 511–22. http://dx.doi.org/10.1590/s0365-05962005000600010.
Повний текст джерелаCarvalho, João Batista Vieira de, Andy Petroianu, Eduardo Travolo, Alberto Brasil Barbosa Duarte, and Benhur Heleno de Oliveira. "IMUNODEPRESSÃO INDUZIDA POR TALIDOMIDA E CICLOSPORINA EM TRANSPLANTE CARDÍACO HETEROTÓPICO DE COELHO: AVALIAÇÃO DA SOBREVIDA E DA REJEIÇÃO AO ENXERTO." Brazilian Journal of Transplantation 7, no. 4 (September 1, 2004): 188–92. http://dx.doi.org/10.53855/bjt.v7i4.314.
Повний текст джерелаLaffitte, E., and J. Revuz. "Talidomida en dermatología." EMC - Dermatología 44, no. 1 (January 2010): 1–10. http://dx.doi.org/10.1016/s1761-2896(10)70337-x.
Повний текст джерелаLeandro, José Augusto, and Francieli Lunelli Santos. "História da talidomida no Brasil a partir da mídia impressa (1959-1962)." Saúde e Sociedade 24, no. 3 (September 2015): 991–1005. http://dx.doi.org/10.1590/s0104-12902015130976.
Повний текст джерелаCarvalho, João Batista Vieira de, and Andy Petroianu. "Imunodepressão induzida por talidomida e ciclosporina em transplante cardíaco heterotópico de coelho." Revista do Colégio Brasileiro de Cirurgiões 30, no. 2 (April 2003): 106–13. http://dx.doi.org/10.1590/s0100-69912003000200005.
Повний текст джерелаOliveira, Maria Auxiliadora, Jorge Antônio Zepeda Bermudez, and Arthur Custódio Moreira de Souza. "Talidomida no Brasil: vigilância com responsabilidade compartilhada?" Cadernos de Saúde Pública 15, no. 1 (January 1999): 99–112. http://dx.doi.org/10.1590/s0102-311x1999000100011.
Повний текст джерелаValente, Maria do Socorro da Silva, and José Luiz Fernandes Vieira. "Talidomida usada por pacientes com eritema nodoso hansênico." Revista da Sociedade Brasileira de Medicina Tropical 43, no. 2 (April 2010): 201–4. http://dx.doi.org/10.1590/s0037-86822010000200019.
Повний текст джерелаДисертації з теми "Talidomide"
Tacchetti, Paola <1977>. "Telcade-talidomide-desametasone vs talidomide-esametasone e doppio trapianto autologo nel mieloma multiplo di nuova diagnosi: risultati di uno studio prospettico randomizzato." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2010. http://amsdottorato.unibo.it/2420/1/tacchetti_paola_tesi.pdf.
Повний текст джерелаTacchetti, Paola <1977>. "Telcade-talidomide-desametasone vs talidomide-esametasone e doppio trapianto autologo nel mieloma multiplo di nuova diagnosi: risultati di uno studio prospettico randomizzato." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2010. http://amsdottorato.unibo.it/2420/.
Повний текст джерелаRenzulli, Matteo <1979>. "Terapia di prima linea del mieloma multiplo con talidomide-desametasone: identificazione di una "signature" predittiva dell'ottenimento della risposta completa mediante studio del profilo di espressione genica." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2007. http://amsdottorato.unibo.it/180/1/TESI_DI_DOTTORATO_MATTEO_RENZULLI.pdf.
Повний текст джерелаRenzulli, Matteo <1979>. "Terapia di prima linea del mieloma multiplo con talidomide-desametasone: identificazione di una "signature" predittiva dell'ottenimento della risposta completa mediante studio del profilo di espressione genica." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2007. http://amsdottorato.unibo.it/180/.
Повний текст джерелаBastos, Fábio da Silva Tavares. "Talidomida: a fénix renascida das cinzas." Master's thesis, [s.n.], 2013. http://hdl.handle.net/10284/4083.
Повний текст джерелаA talidomida marcou o seu nome na história pelas piores razões devido às malformações congénitas que causou em crianças nas décadas de 50 e 60 do século passado. Recentemente descobriram-se novas aplicações clínicas que prometem relançar a maneira como esta molécula é vista pela comunidade científica e a sociedade em geral. Por essa razão, neste trabalho foi feita uma revisão farmacocinética, explorando os principais parâmetros, e uma revisão farmacodinâmica, demonstrando o nosso conhecimento até à data sobre o seu mecanismo de ação. Foi igualmente realizado um levantamento dos principais efeitos secundários e possíveis interações da talidomida, bem como uma compilação dos dados relativos à eficácia da talidomida em doenças dermatológicas, gastrointestinais, tumores não-sólidos e sólidos, bem como em várias outras patologias. O potencial desta molécula é enorme embora só esteja autorizada até ao momento para o tratamento do Eritema Nodoso da Lepra e do Mieloma Múltiplo, neste último em associação com a dexametasona. A sua utilização cada vez maior e o risco de teratogenia ainda real levaram ao desenvolvimento do programa STEPS pela empresa Celgene, que promove o controlo da prescrição, da dispensa e o uso racional da talidomida. The molecule thalidomide carved its name in history for the worst reasons, mostly due to the malformations brought upon children in the 5th and 6th decades of the last century. Recently, new found uses for this drug have promised to remodel its insight from the scientific community as well the general public. So it was necessary to revise all data, pharmacokinetic, with the various parameters, and pharmacodynamics, exploring its mechanism of action, at least as far as it has been revealed. A compilation of data from side effects and possible interactions was performed and the next step involved the gathering of information about its possible effectiveness and significance in various diseases, such as dermatologic, gastrointestinal, oncological non-solid and solid tumors, as well as other varied pathologies. Within it, lays the clinical utility of thalidomide in the only two diseases for which treatment it has been approved for, Erythema Nodosum Leprosum, and Multiple Myeloma, the latter in combination with dexamethasone. Its recent found uses and more growing have led to the development of the STEPS program by the Celgene company, which promotes the control of the prescription, dispense, and rational use of thalidomide.
Kowalski, Thayne Woycinck. "Embiopatia da talidomida : aspectos clínicos e moleculares da teratogênese." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2015. http://hdl.handle.net/10183/119608.
Повний текст джерелаThalidomide was synthesized in 1954 in Western Germany and marketed around the world as a safe sedative, although with the increased incidence of children born with congenital anomalies, especially limb reduction defects (LRD) in the beginning of the 1960s, its teratogenesis was established. It is estimated that 20-50% of all babies exposed to thalidomide were born affected by its embryopathy, counting 10 thousand children around the world. The majority of individuals with thalidomide embryopathy (TE) were evaluated only at birth and the natural history of this condition is not known. Besided, the molecular mechanisms of its teratogenesis were never completely elucidated. Researches in animal models suggest that such mechanism may be associated to thalidomide’s antiangiogenic property. The objective of this study was to perform an exploratory evaluation of physical and psychological health in individuals with TE, in order to provide a better understanding of the embryopathy’s etiology, once it is not known if thalidomide may cause late effects, such as aggravation or anticipation of some diseases. Besides, an evaluation of functional polymorphisms in genes of angiogenesis pathway was performed in these subjects looking for a comprehension of phisiopathological mechanisms of this condition. Through a clinical questionnaire applied to twenty-eight individuals with TE, born between 1959 and 2010, their congenital anomalies were evaluated. Limb defects were the anomalies most frequently identified (96%), followed by eyes (25%) and ears (14%). Twenty-three of these individuals answered a questionnaire about their history and current health. All were adults, with ages ranging between 19 and 55 years. When compared the data obtained with prevalence rates in Brazilian population, without congenital anomalies, it was identified that these individuals present a high prevalence of chronic diseases (p=0.001), especially psychological disorders (p=0.011). A suggestion of early development of cardiovascular diseases was also identified in TE cases (p=0.009). Progressive deafness and dental loss in teenage years were also reported. New analysis must be performed in order to clarify if such conditions may have been caused or aggravated by thalidomide’s embryonary exposure. To evaluate variants of possible genetic susceptibility to TE, it was selected ten functional polymorphisms in genes that seem to have their expression altered after thalidomide’s exposure (according to experimental studies): three in NOS2 gene (rs2779249, rs3833912 and rs2297518), three in PTGS2 (rs689465, rs689466 and rs20417) and four in VEGFA (rs699947, rs1570360, rs2010963 and rs3025039). Such polymorphisms were genotyped through conventional PCR or real-time PCR in 38 individuals with TE and 136 Brazilian without congenital anomalies. It was not identified risk or protective alleles or genotypes to TE in the polymorphisms of NOS2, PTGS2 and VEGFA in the individuals evaluated. Additionally, three polymorphisms in NOS3 were also analyzed: two functional variants (rs2070744 and rs1799983) previously related with TE and the polymorphism rs61722009, of variable number of repeats (VNTR). The frequencies of the variant rs2070744 in the individuals with the embryopathy when compared to control group, without congenital anomalies, was statistically different (p=0.022). Besides, it was demonstrated an interaction between the SNP rs2070744 and the VNTR rs61722009 that corroborated the previous results and suggested that the individuals with TE have, in higher frequency, alleles that reduce the NOS3 expression through pre-transcriptional regulation mechanisms. This finding can be of great contribution to the studies of TE etiology. The analysis and obtained results of this study may complement the assays with animal models and thalidomide that are currently being evaluated, and clarify molecular aspects of the teratogenesis of this embryopathy.
Leite, Ana Lourdes Almeida e. Silva. "Perfil farmacocinético da talidomida nas doses de 200mg e 400mg em voluntários sadios do sexo masculino." reponame:Repositório Institucional da UFC, 2012. http://www.repositorio.ufc.br/handle/riufc/4828.
Повний текст джерелаSubmitted by denise santos (denise.santos@ufc.br) on 2013-05-20T11:24:30Z No. of bitstreams: 1 2012_dis_alasleite.pdf: 3633739 bytes, checksum: 753055b8237138e05a742952154a673a (MD5)
Approved for entry into archive by Erika Fernandes(erikaleitefernandes@gmail.com) on 2013-05-20T12:59:58Z (GMT) No. of bitstreams: 1 2012_dis_alasleite.pdf: 3633739 bytes, checksum: 753055b8237138e05a742952154a673a (MD5)
Made available in DSpace on 2013-05-20T12:59:58Z (GMT). No. of bitstreams: 1 2012_dis_alasleite.pdf: 3633739 bytes, checksum: 753055b8237138e05a742952154a673a (MD5) Previous issue date: 2012
Formulation of thalidomide 100mg tablet was evaluated for its bioavailability (Thalidomide, Fundação Ezequiel Dias - FUNED) in 24 healthy male volunteers. The study conducted was open, randomized, with two treatments, and with a two-period crossover design, during which the volunteers were administered 200mg or 400mg of thalidomide with a seven day washout period. Plasma was obtained over a 36h interval. The thalidomide concentrations were analyzed by combined reversed phase liquid chromatography and tandem mass spectrometry (LC-MS-MS) with positive ion electrospray ionization using selected daughter ion monitoring (MRM). The pharmacokinetic data (mean ± standard deviation) obtained from the formulations containing thalidomide 200mg and 400mg were 12663.54 ± 23056.11 2123.99 and 3437.08ng * h/mL for AUC0-24, 13282.84 ± 2065.91 and 26292.67 ± 4187.85ng * h/mL for AUC0-∞, 861.58 ± 187.30 and 1131.63 ± 266.93ng/mL for Cmáx, 4.52 ± 1.53 and 6.88 ± 4.71h to Tmáx, 6.89 ± 1.44 and 11.01 ± 4.36h to t1/2, 0.10 ± 0.02 and 0.07 ± 0.03 1/h for Ke, respectively. The comparison between pharmacokinetic parameters, at doses of 200 and 400mg, presented proportional curves. When comparing the pharmacokinetic parameters of this study and those found in studies of TEO et al., 1999, NOORMOHAMED et al., 1999 and PAGANOTTO, 2002 it was observed that the FUNED formulation presents smaller and slower absorption than the others
Uma formulação de talidomida comprimido 100mg foi avaliada quanto a sua biodisponibilidade (Talidomida, Fundação Ezequiel Dias - FUNED) em 24 voluntários saudáveis do sexo masculino. O estudo realizado foi aberto, randomizado, cruzado, com dois tratamentos, dois períodos (duas sequências), nos quais os voluntários recebem, em cada período distinto, 200mg ou 400mg da talidomida com intervalo de sete dias entre os internamentos. O plasma foi obtido de um intervalo de 36 horas. As concentrações de talidomida foram analisadas por combinação de cromatografia líquida de alta eficiência (HPLC) acoplada à espectrometria de massas (MS-MS), com ionização em electrospray positivo (MRM). Os dados farmacocinéticos (média ± desvio padrão) obtidos para as formulações contendo talidomida de 200mg e 400mg foram 12663,54 ± 2123,99 e 23056,11 ± 3437,08ng*h/mL para AUC0-24, 13282,84 ± 2065,91 e 26292,67 ± 4187,85ng*h/mL para AUC0-∞, 861,58 ± 187,30 e 1131,63 ± 266,93ng/mL para Cmáx, 4,52 ± 1,53 e 6,88 ± 4,71h para Tmáx, 6,89 ± 1,44 e 11,01 ± 4,36 h para t1/2, 0,10 ± 0,02 e 0,07 ± 0,03 1/h para Ke, respectivamente. A comparação dos parâmetros farmacocinéticos, nas doses de 200 e 400mg, apresentou curvas proporcionais. Quando comparado os parâmetros farmacocinéticos deste estudo e os encontrados nos estudos de TEO et al., 1999, NOORMOHAMED et al., 1999 e PAGANOTTO, 2002 foi evidenciado que a formulação FUNED apresenta absorção menor e mais lenta que as demais
Silva, Marcos Antônio Martins da. "Avaliação do efeito da talidomida sobre os danos intestinais e hepáticos induzidos pela indometacina em ratos wistar." reponame:Repositório Institucional da UFC, 2011. http://www.repositorio.ufc.br/handle/riufc/6900.
Повний текст джерелаSubmitted by denise santos (denise.santos@ufc.br) on 2013-12-05T13:49:59Z No. of bitstreams: 1 2011_dis_mamsilva.pdf: 1357367 bytes, checksum: 3c6be5c64f07e356b2b593d0725b0872 (MD5)
Approved for entry into archive by denise santos(denise.santos@ufc.br) on 2013-12-05T13:50:19Z (GMT) No. of bitstreams: 1 2011_dis_mamsilva.pdf: 1357367 bytes, checksum: 3c6be5c64f07e356b2b593d0725b0872 (MD5)
Made available in DSpace on 2013-12-05T13:50:19Z (GMT). No. of bitstreams: 1 2011_dis_mamsilva.pdf: 1357367 bytes, checksum: 3c6be5c64f07e356b2b593d0725b0872 (MD5) Previous issue date: 2011
The clinical use of indomethacin, although effective in suppressing pain, fever and inflammation is often associated with deleterious effects for the gastrointestinal system, and hematological and renal functions, which limit its therapeutic use. This study examined in rats whether thalidomide could reduced the lethality induced by indomethacin and hematological, biochemical, blood, and intestinal damage. This study analyzed the effect of thalidomide on the intestinal epithelium and increased levels of plasma fibrinogen induced by indomethacin in rats. The rats were treated with indomethacin (5.0 mg / kg), thalidomide 100.0 mg / kg or 200.0 mg / kg, and ampicillin (200.0 mg / kg) orally over a period of 5 days. The animals were submitted to blood collection on the fifth day of treatment by puncturing the orbital plexus of the eye, after being anesthetized with ether. The blood was placed in tubes containing anticoagulant, EDTA, sodium citrate and 3.8% in tubes without anticoagulant. The parameters studied were: erythrogram, leukocyte count, prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, platelet count, and culture of peritoneal lavage, measurement of MPO and evaluation of liver function (ALT, AST, FA, GGT and glucose). The results of the PT, APTT, antithrombin, platelet counts remained normal in the control group. In animals treated with indomethacin, we observed a significant increase (p <0.001) in fibrinogen levels (637.50 ± 13.19 mg / dL) and this increase reversed by treatment with thalidomide 100.0 mg / kg or 200.0 mg / kg, (381.80 ± 50.79 mg / dL, 389.30 ± 65.13 mg / dL, respectively). Animals that received indomethacin were positive in 100% of the cultures performed for enterobacteria, thus demonstrating the presence of bacteria in the gastrointestinal tract into the peritoneal cavity, probably due to a drug-induced intestinal perforation. The MPO activity in peritoneal fluid of rats given indomethacin (5.0 mg / kg, po, 5d) was significantly higher (1217 ± 341.4 U / mL) compared with the control group (3.33 ± 3, 33 U / mL). Treatment with thalidomide (100 or 200 mg / kg, vo, 5d) significantly reversed this effect (p <0.05), (375.8 ± 149.1 U / mL). As inhibition of 69.2%. The results showed that inflammatory intestinal injury in rats induced by indomethacin was partially reversed by treatment with thalidomide. In addition, the data showed a hepatoprotective effect of thalidomide against indomethacin, by its anti-inflammatory activity that might prevent the increase of fibrinogen and leukocyte recruitment in the liver environment.
O uso clínico de indometacina, embora eficaz na supressão da dor, febre e inflamação, é frequentemente associado a efeitos deletérios sobre o sistema gastrointestinal, hematológico e renal, que limitam o seu uso terapêutico. Este estudo analisou se a talidomida poderia reduzir a letalidade induzida pela indometacina e as alterações hematológicas e bioquímicas no sangue, os danos intestinais, além do efeito da talidomida sobre o epitélio intestinal e o aumento nos níveis de fibrinogênio plasmático induzido pela indometacina em ratos. Os ratos foram tratados com indometacina (5,0 mg/kg), talidomida 100,0 mg/kg e 200,0 mg/kg, e ampicilina (200,0 mg/kg), via oral, num período de cinco dias. Os animais foram submetidos à coleta de sangue no quinto dia de tratamento, mediante a punção do plexo-orbital do olho. Os parâmetros estudados foram: eritrograma, contagem de leucócitos, tempo de protrombina (TP), tempo de tromboplastina parcial ativada (TTPA), fibrinogênio, contagem de plaquetas, cultura do lavado peritoneal e dosagem de mieloperoxidase (MPO) nesse lavado, avaliação hepática (ALT, AST, FA, GGT) e glicose. Os resultados do TP, TTPA, antitrombina, contagem de plaquetas, mantiveram-se normais em relação ao grupo controle. Nos animais tratados com indometacina, observamos um aumento (p <0,001) nos níveis de fibrinogênio (637,50±13,19 mg/dL) sendo o mesmo revertido pelo tratamento com talidomida 100,0 mg/kg e 200,0 mg/kg, (381,80 ± 50,79 mg/dL; 389,30± 65,13 mg/dL) respectivamente. Os animais que receberam indometacina apresentaram positividade em 100% das culturas realizadas para enterobactérias, demonstrando assim a presença de bactérias do trato gastrintestinal na cavidade peritoneal. A atividade da MPO no líquido peritoneal dos ratos que receberam indometacina (5,0 mg/kg, v.o, 5d) foi significativamente maior (1217 ± 341,4 U/mL) quando comparada com o grupo-controle (3,33 ± 3,33 U/mL). O tratamento com talidomida (100 e 200 mg / kg, v.o, 5d) reduziu significativamente (p <0,05) este aumento (375,8 ± 149,1 U/ mL), sendo a inibição de 69,2%. Os resultados demonstram que a lesão intestinal inflamatória induzida pela indometacina foi revertida parcialmente pelo tratamento com a talidomida. Além disso, os dados obtidos evidenciam o efeito hepatoprotetor da talidomida contra a indometacina, provavelmente por sua atividade antiinflamatória diminuindo ou minimizando o aumento do fibrinogênio e recrutamento leucocitário no ambiente hepático.
Vianna, Fernanda Sales Luiz. "Talidomida no Brasil : vigilância epidemiológica, teratogênese e farmacogenética." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2013. http://hdl.handle.net/10183/142682.
Повний текст джерелаDespite the thalidomide tragedy which occurred more than 50 years ago and the medication still being widely used, several issues remain unsolved regarding its teratogenicity. Cases of thalidomide embryopathy (TE) are still being registered and molecular processes that cause malformations from in utero exposure have not yet been fully identified. In this work, our goal was to implement a surveillance system to identify TE in Brazil and identify targets that underlie pharmacogenetic responses to thalidomide. We conducted a hospital-based pilot study to establish surveillance of the Thalidomide Embryopathy Phenotype (TEP) and to evaluate the viability of such surveillance. We identified a higher prevalence of TEP in the surveillance period from 2000 to 2008 (3.10/10,000 births, 95% CI: 2.50 to 3.70) compared to the baseline period from 1982 to 1999 (1.92/10,000 births, 95% CI: 1.60 to 2.20), coinciding with a higher availability of thalidomide in Brazil. This tool was later applied at the national level through of Birth Certificates (declaration of live birth known as a DNV in Brazil) which is an official record that is mandatory for all live births in the country. In this surveillance, clusters and geographical isolates of TEP were identified. Moreover, we observed a direct correlation between the amount of thalidomide dispensed and the occurrence of this screening phenotype: for every 100,000 tablets dispensed, there is a new case of TEP. This is the first direct correlation observed after the tragedy of the 1960s. Investigations of polymorphisms in genes that are susceptible to teratogenesis caused by thalidomide have been developed using hypotheses generated by animal models: (1) inactivation of the E3 ubiquitin ligase complex by binding of thalidomide to CRBN which is the protein part of this complex; (2) decreased gene expression in embryonic development; and (3) anti-angiogenic mechanisms. Individuals without malformations and with TE were compared in regards to the genetic constitution of the region encoding 104 amino acids which are in the region where thalidomide binds to CRBN. In this region, where CRBN is highly conserved, ten variants were identified: nine in intronic regions and one in the 3' untranslated region (3'UTR). The rare variants (less than 1%) were shown to be more present in patients with TE than in those unaffected. The analysis of single nucleotide polymorphisms (SNPs) in several genes that are important for both embryonic development (FGF8, FGF10, BMP4, SHH, and TP53) and metabolization of thalidomide (CYP2C19 and TNF-alpha) did not differ between individuals with or without malformations. However, the analysis of a polymorphism in the promoter of the gene encoding the endothelial nitric oxide synthase (eNOS) – an enzyme that synthesizes nitric oxide and is an important molecule in angiogenesis – showed that the variants associated with decreased activity in this enzyme were present more often in individuals with TE than in those without birth defects (p = 0.03). The pharmacogenetics aspects of thalidomide used in treating erythema nodosum leprosum (ENL) – the main use of thalidomide in Brazil – have also been studied by analyzing polymorphisms in thalidomide metabolization genes and prednisone which is normally used with thalidomide for treating ENL. A preliminary assessment of polymorphisms in both metabolic pathways of these drugs (in the NR3C1, ABCB1, CYP2C19 and TNF-alpha genes) seems to indicate that there is no influence in the thalidomide and prednisone doses for the treatment of ENL. However, these results may be of limited use because they included very heterogeneous clinical situations in which different doses were required for each drug. Pharmacoepidemiological data presented in this study reinforce the need for continued vigilance of TE in Brazil and for special attention to be given to the dispensing of this drug, especially in areas where leprosy is endemic. Furthermore, our work suggests that angiogenesis-related genes may confer an increased susceptibility to ET and that the CRBN gene should be investigated in more detail in order to understand the role of rare variants in this condition and to generate new insights into teratogenic mechanisms so that safer thalidomide analogues can be developed.
Burgos, Bravo Valentina. "El abandono de las víctimas de talidomida en Chile." Tesis, Universidad de Chile, 2015. http://repositorio.uchile.cl/handle/2250/132309.
Повний текст джерелаEl autor no autoriza el acceso a texto completo de su documento
El 28 de octubre en la mañana sonó el teléfono de César Rodríguez. Como todos los días, se encontraba en su oficina en Senadis (Servicio Nacional de Discapacidad), donde trabajaba en la sección de atención a público. Al mirar el celular, notó que la llamada correspondía a su amiga y compañera de ideales, María Isabel Cantillana (49). Era común que ambos conversaran durante la semana, sobre todo el último tiempo que Isabel había sido diagnósticada con un agresivo cáncer a la médula ósea. Una voz masculina y sombría respondió desde el otro lado y un escalofrío recorrió la espalda de César al intuír el motivo de aquella llamada. Se trataba de un pariente de Isabel, comunicando el fallecimiento de su amiga el día anterior. Se demoró mucho en reaccionar. Ni siquiera el bullicio de la calle Miraflores fue capaz de traerlo a la realidad. Una serie de imágenes cruzaron su mente: marchas, asados y reuniones con el resto de la organización que ambos integran. Tanto César como María Isabel forman parte de Vitachi (Víctimas de Talidomida en Chile), organización que desde el 2009 busca la reparación por parte del Estado por el daño cometido al permitir el ingreso y la posterior comercialización del medicamento Talidomida en el mercado. Dicho remedio, al ser ingerido por madres durante el primer trimestre del embarazo, daba como resultado el nacimiento de niños con extremidades inferiores y superiores más cortas de lo normal. Ambos se conocieron en esa cruzada, así como el resto de los treinta y nueve integrantes que conforman la organización. María Isabel siempre fue de las más entusiastas, organizando marchas y reuniones que no bajaran los ánimos pese a las constantes negativas que desde el 2009 reciben por parte del Estado chileno. “María Isabel murió sin poder tener justicia. Lo más chocante para todos, incluso para ella, fue que su enfermedad fue tratada con Talidomida, la misma que provocó la ausencia de unos de sus brazos. Así de fuerte… y ella falleció, esperando por años que el Estado se hiciera cargo”, cuenta César. La Talidomida ha sido uno de los medicamentos más controversiales de la historia. De origen alemán, la Talidomida fue creada en las dependencias de Chemie Grunenthal, importante cadena farmaceutica que hasta el día de hoy opera en todo el mundo. Fue producto al desastre que provocó a nivel global que fue creada la farmacovigilancia, concepto que promueve la seguridad de los medicamentos que son vendidos a la población. Además, se trata del primer medicamento en la historía que entregó indemnizaciones millonarias a sus víctimas por los daños físicos y sicológicos que dejó durante los años cincuenta y sesenta. En Europa, continente que congrega la mayor cantidad de víctimas, se crearon instituciones al servicio de las madres y de los niños afectados. Pese a ser uno de los países que comercializó el medicamento desde 1961, Chile se encuentra fuera de los conteos internacionales. Esa misma razón impide que se reconozca a las víctimas y que puedan participar de los beneficios de instituciones internacionales. El mismo Estado desconoce la existencia hasta la fecha de víctimas, pese a las evidencias que organizaciones como Vitachi han presentado en múltiples oportunidades a las autoridades de salud, en donde queda en evidencia la comercialización del fármaco que fue entregado en hospitales y centros médicos a lo largo del país. En la actualidad, Vitachi tiene en sus registros 38 víctimas, de las cuales, el 90% de ellas supera los 50 años. La mayor parte de los integrantes de la organización han tenido que costear prótesis, enfermeras y médicos para tratar dolencias asociadas a la discapacidad. Trámites, comisiones y reuniones. Compromisos de autoridades y vuelta a la negociación. Así como María Isabel, muchas de ellas quizás se marchen sin respuesta y sin justicia, esperando por parte del Estado una restauración que les permita vivir una vida con dignidad y tranquilidad. Una respuesta que lleva más de seis años esperando ser resulta. Una justicia que tres gobiernos no han podido resolver.
Книги з теми "Talidomide"
United States. Food and Drug Administration, ed. La Talidomida: Importante informacion para el paciente. [Washington, D.C.?: Health and Human Services, Public Health Service, Food and Drug Administration, 1996.
Знайти повний текст джерелаЧастини книг з теми "Talidomide"
Budin, Jesse, Renato Salla Braghin, and Leonel Piovezana. "A ESCOLARIZAÇÃO DE PESSOAS COM SÍNDROME DA TALIDOMIDA." In Educação: Diálogos convergentes e articulação interdisciplinar 4, 9–19. Atena Editora, 2021. http://dx.doi.org/10.22533/at.ed.9902122092.
Повний текст джерелаSantacruz-Ortega, María del Pilar. "Teratología conductual: un apasionante campo de trabajo transdisciplinar." In Investigación en psicología: aplicaciones e intervenciones II, 193–214. Editorial Universidad Católica de Colombia, 2022. http://dx.doi.org/10.14718/9786287554320.2022.9.
Повний текст джерелаТези доповідей конференцій з теми "Talidomide"
Leite, Sarah de Maciel, Leticia Polezuk Scaramussa, Maria Eduarda Fernandes Nunes, Antonio Victor dos Anjos Viana, and Leonardo Lora Barraza. "USO DE TALIDOMIDA NO MANEJO DE PRURIGO NODULAR." In III Congresso Online Brasileiro de Medicina. Congresse.me, 2022. http://dx.doi.org/10.54265/fxwg5847.
Повний текст джерелаBUDIN, Jesse, and leonel PIOVEZANA. "A TRAJETÓRIA ESCOLAR DE PESSOAS COM SÍNDROME DA TALIDOMIDA." In Anais do 9º Seminário Integrado de Ensino, Pesquisa e Extensão da Unochapecó. Recife, Brasil: Even3, 2019. http://dx.doi.org/10.29327/15332.1-12.
Повний текст джерелаSaviane, Maiara, and FLÁVIA CRISTIANE VIEIRA DA SILVA. "Uma proposta de ensino a partir de uma situação-problema sobre a história da talidomida." In 20º Encontro Nacional de Ensino de Química. Recife, Pernambuco: Even3, 2021. http://dx.doi.org/10.29327/eneqpe2020.247589.
Повний текст джерелаSilva, Renata Albuquerque da, Dyanne Katya Pereira Freitas, and Rafaela Vieira de Souza. "IMPACTO DA COVID-19 EM PACIENTES COM HANSENÍASE." In I Congresso Brasileiro de Doenças Infectocontagiosas On-line. Revista Multidisciplinar em Saúde, 2021. http://dx.doi.org/10.51161/rems/2748.
Повний текст джерела